

Core Purpose : To continuously delight our customers by offering trustworthy services for Wealth creation

Core Values : We meet Statutory and Non-statutory Obligations on Due date.
We do not encourage speculation. Right attitude towards Clients.
Client is always Right. Client deserves Trustworthy Advice. We are Trustee of Client's Assets when in our Custody.

Our Mission : To pursue Quality Advice and Ontime Services in Healthy Atmosphere leading to benefit of all Stakeholders

Index and data indicators

Indian indices marked lowest closing in December 2011, so data near to the month is taken for reference, RBI FY27 GDP growth forecast at 6.6%

Time Period	31-08-2026	31-08-2025	30-12-2011
Nifty	24080.4	24426.85	4324.3
Valuation			
Trailing PE	20.36	21.46	16.75
Trailing PB	2.92	3.27	2.76
Mcap/GDP	1.07	1.14	0.69
Nifty Return CAGR			
1year	-1.42%	-3.21%	-24.62%
2year	-2.32%	12.64%	-5.71%
3year	7.74%	11.21%	16.04%
EPS growth CAGR			
1year	3.91%	5.86%	10.17%
2year	4.88%	13.97%	10.90%
3year	10.51%	10.76%	6.56%
Other data points			
Credit growth	18.30%	10.20%	16.80%
10-year bond yield	6.94	6.50	8.56
Brent Oil Futures	90.49	68.12	107.38
USD/INR	95.16	88.17	53.05
Gold (oz/USD)	4481.5	3512	1564.3

Source: RBI, NSE, Sajag Research

MARKET REVIEW

Nifty declines!

Nifty remained under pressure through the month of August as it declined for four straight weeks. Weak sentiment was driven by SEBI's new closing-auction volatility, elevated crude prices, renewed US-Iran tensions, and sustained FII selling.

Key developments during the month were,

- ▶ Retail inflation (CPI) rose further to 4.45% in July, a 19-month high and the second straight month above the RBI's 4% target - up from 4.38% in June. Rural inflation climbed to 4.84% (from 4.74%). WPI eased marginally to 9.78% in July from 9.87% in June. Fuel and power inflation dropped sharply to 20.05% (from 27.41%) as mineral oil and crude prices softened, but this was the only relief. Primary articles inflation rose to 8.52% (from 7.0%) and manufactured products climbed to 8.29% (from 7.48%). The WPI Food Index hit a 19-month high of 6.65% (from 6.14%).
- ▶ India's IIP growth moderated to 6.7% in July, easing from June's upwardly revised 8.8% (up from the initial 7.3% estimate). Manufacturing grew 7.3%, electricity and gas supply surged 8.7% (driven mainly by non-renewable generation, up 12.5%), while mining and quarrying turned into a drag, contracting 0.9% - a sharp reversal from 10.7% growth a year earlier, weighed down by a 12.5% fall in non-metallic minerals even as metallic minerals (including rare earths) jumped 24.3%.


- ▶ India's fiscal deficit for the first four months of FY27 (April-July 2026) stood at ₹4.55 lakh crore, or 26.8% of the full-year Budget Estimate of ₹16.96 lakh crore, an improvement from 29.9% in the same period last year, meaning the deficit is actually running lower despite higher spending. Net tax revenue came in strong at ₹8.45 lakh crore, or 29.5% of the annual target (up from 23.3% a year earlier), Capital expenditure jumped 30% YoY to ₹4.51 lakh crore, reaching 37% of the full-year capex target of ₹12.22 lakh crore, up from 31% a year ago, confirming the investment-led spending push has continued to accelerate rather than plateau. Total expenditure for the four months came in at about ₹17.62 lakh crore, or 32.9% of BE (versus 30.9% last year).
- ▶ India's merchandise trade deficit widened further to a six-month high of \$31.98 billion in July - up from \$27.88 billion a year earlier - as goods imports rose 17.5% YoY to a nine-month high of \$76.22 billion. Merchandise exports for the month, up 19.6% YoY to \$44.24 billion. Services exports rose to \$35.89 billion (from \$33.74 billion), keeping the services surplus intact, but the overall (goods plus services) trade deficit still widened sharply - up 31.5% YoY to \$15.03 billion, from \$11.43 billion a year ago. For the cumulative April-July FY27 period, the overall trade deficit has jumped 53% YoY to \$49.43 billion (from \$32.32 billion), with merchandise imports growing faster (19.3%) than merchandise exports (17.0%).
- ▶ GST collections rose 13.9% YoY to ₹1.95 lakh crore in June, with net collections up 11.2% to ₹1.62 lakh crore despite a sharp rise in refunds; import-linked GST revenue surged 34.6%.
- ▶ India's real GDP grew 7.8% year-on-year in Q1 FY27 (April-June 2026), beating the Reserve Bank of India's 7% projection. GDP growth moderated from the revised 8.6% recorded in Q4 FY26. The stronger-than-expected growth points to resilient domestic economic activity, although investors will continue to track crude oil prices, inflation and geopolitical risks.

At its July meeting, the Federal Reserve kept the federal funds rate unchanged at 3.50%-3.75%, where it has stood since June 2026 under Chair Kevin Warsh. The FOMC maintained a hawkish stance focused squarely on inflation containment, backed by an upward revision of the 2026 PCE inflation forecast to 3.6% (up from 2.7%) due to persistent service and shelter cost pressures.

Global equities despite a late-month increase in geopolitical and inflation concerns, remained mixed in the last month. The MSCI All Country World Index gained about 2.7%, while emerging markets outperformed developed markets, rising 3.4% in US-dollar terms. The key drivers were strong corporate earnings, continued AI/semiconductor enthusiasm, a relatively resilient global economy and a weaker US dollar. S&P 500 rose 2.7%, Nasdaq rose 4.2%, DJIA rose 1.5%, Nikkei rose 3.3%. However, this was increasingly accompanied by rising bond yields

Market Outlook

Though Indian markets remain a laggard in the month of August, foreign investors, meanwhile,



Performance of key sectoral indices

Nifty IT	2.47%	Nifty Metal	0.43%
Nifty FMCG	1.24%	Nifty Auto	0.38%
Nifty Bank	1.18%	Nifty Infrastructure	0.32%
Nifty MNC	1.04%	Nifty Energy	0.27%
Nifty Consumption	0.75%	Nifty Pharma	-0.38%
Nifty Realty	0.68%		

were actually quite constructive. Foreign portfolio investors invested more than \$3.2 billion in Indian equities during August, their strongest monthly inflow since September 2024, even as the headline indices declined, suggesting broader strength in the Indian markets.

- ▶ In the US, CPI decreased to 333.92 points in July from 333.95 points in June of 2026. The annual inflation rate in the US slowed for a second consecutive month to 3.4% in July 2026, from 3.5% in June, in line with expectations. Industrial Production in the United States increased 1.1% in July of 2026 over the same month in the previous year. US construction spending also weakened, falling 0.5% in July to a seasonally adjusted annual rate of \$2.158 trillion. The decline added to signs of softer activity in parts of the US economy. The US ISM Manufacturing PMI eased to 54.6 in August from 55.6 in July, indicating that manufacturing activity continued to expand, but at a slower pace. The New Orders Index declined to 53.7 from 56.7, while the Employment Index fell to 51.2 from 52.8. The Prices Index remained elevated at 71.1, pointing to continued input-cost pressures. The US labour market remained relatively resilient, with JOLTS job openings rising by 89,000 to 7.271 million in July. However, hiring fell by 278,000 to 5.054 million, while the hires rate declined to 3.2%, suggesting some moderation in labour-market momentum despite continued demand for workers. US labour-market data remained a key focus.
- ▶ China's H1 2026 real GDP expanded 4.7% YoY to \$10.25 trillion USD, remaining within the government's 4.5%-5% full-year target, though quarterly momentum moderated from 5% in Q1 to 4.3% YoY in Q2. Macroeconomic disinflation continued as headline CPI dropped to 0.5% YoY in July due to declining food prices (-1.5%), while core CPI slowed to 0.9%. Industrial resilience remained a key bright spot, with 7-month industrial profits rising 17.6% YoY to CNY 4.58 trillion, driven by explosive growth in high-tech sectors like computer, communication, and electronic equipment (+110.0%). The external trade balance expanded to a \$112.50 billion surplus in July as exports surged 23.9% YoY to \$397.85 billion, buoyed by strong global demand for AI technology products and front-loading shipments ahead of a new 12.5% US tariff rate. In contrast, domestic consumption remained severely depressed, with July retail sales growing just 0.6% YoY alongside sharp drops in big-ticket items like automobile sales (-17.0%), while ongoing real estate adjustments dragged down fixed asset investment.
- ▶ The Eurozone economy demonstrated resilience in mid-2026 as Q2 GDP expanded 0.4% QoQ (surpassing 0.2% forecasts) and the S&P Global Eurozone

Composite PMI held firm at 52 in August, driven by steady new orders, a recovery in services, and the region's first expansion in export orders and net employment growth this year. However, mounting geopolitical tensions in the Middle East and US-Iran frictions triggered severe energy market disruptions, driving producer prices up 1.6% MoM in July (5.8% YoY) following a 5.6% single-month energy cost spike. These upstream pressures fed directly into consumer prices, lifting headline inflation from a low of 2.8% YoY in June to 2.9% in July and 3.3% in August, its highest level since late 2023, with energy inflation jumping 14.3% YoY. The inflationary pickup broadened across key economies, with August headline figures reaching 4.5% in Spain, 3.2% in Italy, 2.9% in Germany, and 2.7% in France, even as core inflation edged down slightly to 2.4% (and services inflation eased to 3.0%). Meanwhile, trade policy tightened as the EU implemented a 47% reduction in duty-free steel import quotas effective July 1 to safeguard domestic industry.

- ▶ In July 2026, Japan's annual inflation rate accelerated to 1.9% YoY (up from 1.6% in June), driven by a slower decline in electricity costs alongside broad-based price increases across food, transport, household goods, healthcare, and recreation. Housing inflation held steady at 1%, clothing price growth moderated to 1.2%, and education costs remained in deflation at -3.8%. Core CPI (excluding fresh food) rose to a four-month high of 1.8% YoY-matching market expectations-though it remained just below the Bank of Japan's 2% target for a sixth straight month. Looking at broader trends, Japan's 2025 core-core CPI (excluding fresh food and energy) reached 111.9 (+3.2% YoY), while long-term forecasts project inflation to anchor near 2.2% in 2027 and 2.1% in 2028.
- ▶ India's HSBC Manufacturing PMI eased to 52.8 in August 2026 from 53.5 in July, revised down from the preliminary reading of 52.9. The latest reading marked the weakest improvement in the sector's health in five years. Output and new orders continued to expand, but growth in both slowed to their weakest levels since August 2021 amid softer demand and challenging market conditions. Export orders also rose, although growth in international sales moderated from July. Softer demand weighed on purchasing activity and inventories, while manufacturing employment declined for the first time in two-and-a-half years. Business confidence improved to its highest level since May, although it remained subdued by historical standards. Separately, India's HSBC Composite PMI stood at 54.3 in August 2026, down from the flash estimate of 54.6 but unchanged from July, indicating continued private-sector growth. However, the pace remained the joint-slowest in four-and-a-half years. The HSBC Services PMI was revised to 54.1 from the flash estimate of 54.5, up from 53.3 in July, as higher demand and new business supported growth.

India's domestic fundamentals remain resilient, however global cues are overshadowing India's growth outlook. Renewed risk-off sentiment across global markets alongside Fed Chair Kevin Warsh's hawkish inflation warning, lifting the probability of a September rate hike and renewed US-Iran military exchanges and escalating risks surrounding the Strait

of Hormuz, again have brought the uncertainty around. The global equity market outlook remains selectively positive in this environment.

TECHNICAL VIEW

Nifty opened August with a sharp gap-up, attempting to move out of the range and rallied towards 24750-24800, but the move faced strong rejection at higher levels. Nifty thereafter remained under pressure during the month and the decline eventually took the index below 24,000, with the latest price action testing 23,800, indicating that most of the August advance has been unwound. Nifty declined 303.20 points, or 1.24%, on a monthly basis, below its 13-month EMA.

On weekly chart, Nifty has formed a sequence of lower highs and lower lows, with recovery attempts repeatedly facing selling pressure. Nifty has again moved below its 13-55-200 day EMA and 13-55 week EMA. The breakdown below key moving averages indicates weakness. The lower weekly and monthly RSI near 45 shows weakening momentum.

The August swing from approximately 24100 to 24777 places the 61.8% retracement near 24358 (near the 200-day EMA), from where Nifty saw resistance when it attempted a recovery. Going ahead, 23700 is the immediate support, followed by 23300-23000. On the upside, 24000-24100 is the first hurdle, while 24300-24400 remains the key resistance zone.



MUTUAL FUNDS PERFORMANCE

NAV as on 31 August 2026

Return %

Liquid Funds	NAV	30 DAYS	3 MON	6 MON	1 YR
Axis Liquid Fund (G)	3,128.33	0.56	1.76	3.49	6.51
Franklin India Liquid Fund Super Ins (G)	4,229.51	0.56	1.78	3.48	6.51
DSP Liquid Fund (G)	4,009.55	0.55	1.75	3.45	6.47
Arbitrage Funds	NAV	30 DAYS	3 MON	6 MON	1 YR
Kotak Arbitrage Fund (G)	40.07	0.21	1.64	2.83	5.83
ICICI Pru Arbitrage Fund Reg (G)	36.67	0.17	1.62	2.76	5.78
UTI Arbitrage Fund (G)	37.45	0.20	1.56	2.71	5.77
HDFC Arbitrage Fund (G)	32.73	0.12	1.54	2.73	5.74
Hybrid Aggressive Funds	NAV	1 YR	2 YR	3 YR	5 YR
ICICI Pru Aggressive Hybrid Fund (G)	405.01	2.56	3.26	13.34	14.76
Edelweiss Aggressive Hybrid Fund (G)	65.43	3.59	2.21	12.37	11.85
UTI Aggressive Hybrid Fund (G)	406.63	2.17	0.31	10.67	10.77
Hybrid Balanced Advantage Funds	NAV	1 YR	2 YR	3 YR	5 YR
ICICI Pru Balanced Advantage Fund Reg (G)	78.94	5.80	5.79	11.21	10.47
Aditya Birla SL Balanced Advantage Fund (G)	114.05	7.52	5.62	11.19	9.40
Edelweiss Balanced Advantage Fund (G)	53.46	5.97	2.45	9.93	8.40
Tata Balanced Advantage Fund (G)	20.94	3.01	1.52	7.79	7.82
Hybrid Multi-Asset	NAV	1 YR	2 YR	3 YR	5 YR
WhiteOak Capital Multi Asset Allocation Fund Reg (G)	16.20	12.66	13.59	15.82	N/A
Aditya Birla SL Multi Asset Allocation Fund (G)	17.04	13.87	10.58	15.01	N/A
ICICI Pru Multi Asset Fund (G)	814.79	6.54	7.14	14.25	16.78
KOTAK Multi Asset Allocation Fund Reg (G)	15.92	17.38	10.80	N/A	N/A
DSP Multi Asset Allocation Fund Reg (G)	16.20	16.49	13.61	N/A	N/A
Equity Value Funds	NAV	1 YR	2 YR	3 YR	5 YR
HSBC Value Fund (G)	114.77	5.63	1.88	15.69	15.42
Nippon India Value Fund (G)	223.70	0.45	-1.57	14.09	13.42
ICICI Pru Value Fund (G)	457.84	-2.07	-1.04	12.23	14.55
Bandhan Value Fund Reg (G)	147.31	1.50	-2.64	9.65	12.33
Equity Focused Funds	NAV	1 YR	2 YR	3 YR	5 YR
ICICI Pru Focused Fund Reg (G)	94.58	2.80	2.71	16.26	14.55
HDFC Focused Fund (G)	233.62	1.03	3.29	14.96	17.30
Nippon India Focused Fund (G)	123.05	3.04	0.04	9.65	10.43
Franklin India Focused Equity Fund (G)	100.98	-6.49	-4.36	8.09	9.59
Tax Saving Schemes (ELSS)	NAV	1 YR	2 YR	3 YR	5 YR
Motilal Oswal ELSS Tax Saver Fund Reg(G)	57.70	13.45	5.12	21.40	16.04
SBI ELSS Fund Reg (G)	428.88	-0.77	-2.01	14.07	14.49
HDFC ELSS Tax saver Reg (G)	1,372.08	-2.73	-0.35	13.08	13.95
Parag Parikh ELSS Tax Saver Fund (G)	29.13	-8.31	-2.75	8.51	10.45
Large Cap Funds	NAV	1 YR	2 YR	3 YR	5 YR
ICICI Pru Large cap Fund Reg (G)	107.62	-1.96	-1.08	11.21	11.11
Nippon India Large Cap Fund (G)	89.15	-1.90	-0.25	10.90	12.81
Tata Large Cap Fund Reg (G)	506.23	2.44	-0.96	10.24	9.05
HDFC Large Cap Fund (G)	1,128.47	0.09	-1.79	9.73	11.04
Mid Cap Funds	NAV	1 YR	2 YR	3 YR	5 YR
Edelweiss Mid Cap Fund (G)	109.80	9.51	4.96	20.15	17.64
Nippon India Growth Fund (G)	4,512.67	10.01	4.53	18.20	17.75
Motilal Oswal Midcap Fund Reg (G)	104.33	-0.16	0.52	17.71	21.12
HDFC Mid Cap Fund (G)	211.55	10.03	5.38	17.58	18.96

Large & Mid Cap Funds	NAV	1 YR	2 YR	3 YR	5 YR
Invesco India Large & Mid Cap Fund (G)	110.73	9.43	8.20	22.08	16.34
Motilal Oswal Large and Mid Cap Fund Reg (G)	37.37	12.22	7.59	21.80	17.34
Bandhan Large & Mid cap Fund (G)	141.65	6.35	1.84	17.52	15.82
HDFC Large And Mid Cap Fund Reg (G)	348.80	4.00	0.09	12.84	14.32

Small Cap Funds	NAV	1 YR	2 YR	3 YR	5 YR
Bandhan Small Cap Fund (G)	52.18	13.47	4.84	23.79	18.67
Nippon India Small Cap Fund (G)	186.27	10.89	1.65	14.72	18.83
HSBC Small Cap Fund Reg (G)	92.09	14.72	2.28	13.84	17.47
Franklin India Small Cap Fund (G)	180.63	7.12	-1.68	12.46	15.99

Flexicap Funds	NAV	1 YR	2 YR	3 YR	5 YR
HDFC Flexi Cap Fund Reg (G)	2,062.37	3.56	4.09	15.62	17.08
Edelweiss Flexi Cap Fund (G)	39.20	3.72	0.21	13.85	11.70
Parag Parikh Flexi Cap Fund Reg (G)	82.48	-2.72	1.81	12.57	11.33
Franklin India Flexi Cap Fund (G)	1,597.63	-0.92	-1.94	11.15	11.76

Multicap Funds	NAV	1 YR	2 YR	3 YR	5 YR
Axis Multi Cap Fund (G)	19.88	11.69	5.3	19.00	N/A
KOTAK Multi Cap Fund Reg (G)	20.18	7.11	1.27	16.01	N/A
ICICI Pru Multicap Fund Reg (G)	865.73	10.28	3.02	15.96	14.70
Nippon India Multi cap Fund (G)	301.84	0.74	0.5	12.74	16.56
HDFC Multi Cap Fund Reg (G)	18.84	0.44	-2.22	11.17	N/A

Sector & Thematic Funds	NAV	1 YR	2 YR	3 YR	5 YR
ICICI Pru Healthcare Fund (G)	43.29	8.25	6.02	22.15	14.91
Mirae Asset Healthcare Fund (G)	45.70	18.59	8.59	21.64	13.69
DSP India T.I.G.E.R. Fund Reg (G)	363.11	16.52	3.35	19.33	20.85
Kotak Pioneer Fund (G)	35.56	10.11	8.17	18.67	14.44
SBI Banking & Financial Services Fund Reg (G)	43.50	4.79	7.06	15.51	11.63
Bandhan Infrastructure Fund Reg (G)	48.55	-1.54	-6.47	14.46	15.29
ICICI Pru India Opportunities Fund (G)	36.28	3.13	1.31	14.17	17.54
Sundaram Services Fund (G)	36.79	6.33	5.35	13.98	12.75
Tata Banking and Financial Services Fund Reg (G)	44.61	7.22	6.41	11.31	10.95
Aditya Birla SL Consumption Fund Reg (G)	206.12	-7.04	-4.17	8.54	8.80
SBI MNC Fund Reg (G)	413.13	16.03	4.61	7.43	7.93

Index	NAV	1 YR	2 YR	3 YR	5 YR
NSE - Nifty 50	23,897.70	-3.38	-2.62	6.95	6.64
S&P BSE Sensex	76,515.43	-5.21	-3.61	5.24	5.64

**Systematic investment in different equity oriented Mutual funds at the rate of Rs. 10000/- p.m.
and its values at different time intervals.**

Scheme	Value & Return (3 Yr)	%	Value & Return (5 Yr)	%	Value & Return (8 Yr)	%	Value & Return (10 Yr)	%	Value & Return (15 Yr)	%
Total Investment :	360000	%	600000	%	960000	%	1200000	%	1800000	%
Canara Robeco Large & Mid cap Fund Reg (G)	400,443	7.03	785,618	10.71	1,728,793	14.31	2,476,094	13.86	7,266,054	16.88
Aditya Birla SL Consumption Fund Reg (G)	372,841	2.29	727,538	7.63	1,573,599	12.04	2,264,469	12.19	5,762,941	14.21
Kotak Midcap Fund (G)	436,141	12.85	910,301	16.67	2,204,060	20.16	3,179,422	18.51	8,945,142	19.24
Nippon India Small Cap Fund (G)	425,630	11.17	926,513	17.39	2,545,623	23.63	3,735,781	21.49	12,117,567	22.67
SBI Large & MidCap Fund Reg (G)	403,961	7.62	809,882	11.94	1,830,355	15.69	2,622,674	14.94	6,372,957	15.37

*Past performance of Mutual Funds is not an indicator for future performance.

Visit us at **www.sajagonline.com**

COMPANY ANALYSIS REVIEW

GABRIEL INDIA LIMITED

CMP (As on 31 August 2026) – 1437.90

INDUSTRY - AUTO ANCILLARY

SEPTEMBER 2026

SENSEX – 76957 NIFTY – 24080

Mkt. Cap.	: 25483.91 Cr
Equity	: 14 Cr
Trading Vol.	: 896312
52 Week High/Low	: 1600/795
Face Value	: 1

BSE Group	: A
BSE Code	: 505714
NSE Symbol	: GABRIEL
Bloomberg	: GABRIN
Reuters	: GABR.BO

Shareholding Pattern	
Promoters	: 63.55
Institutions & Corporates	: 14.03
Foreign	: 7.19
Public & Others	: 15.23

The stock was earlier reviewed in our Sajag Online publication of June 2024. We continue to maintain a positive outlook of the company given a combination of strong OEM relationships, aftermarket reach, EV and premiumisation opportunities, railway exposure and entry into braking, steering and ADAS which gives Gabriel a broader growth profile alongwith its traditional suspension business.

Gabriel India Limited, the flagship company of the ANAND Group, was established in 1961 and is a leading manufacturer of ride-control products including shock absorbers, struts and front forks. The company supplies two- and three-wheelers, passenger vehicles, commercial vehicles and railways, besides having a strong presence in the aftermarket.

Investment rationale

- Gabriel is among the top players in two-wheelers, a market leader in commercial vehicles and railways with around 88% market share, and holds around 32% share in two- and three-wheeler suspension and 25% in passenger vehicle suspension. The company is expanding beyond its traditional suspension business through sunroofs, automotive fasteners, lubricants and e-fluids, while recent restructuring under Project Rise has consolidated several ANAND Group automotive businesses under Gabriel. New programmes with Hero MotoCorp, TVS Motors, Bajaj Auto, Suzuki, Yamaha, Maruti Suzuki, Tata Motors and Mahindra & Mahindra provide visibility for future volumes.
- In FY26, two- and three-wheelers contributed around 62% of FY26 sales and grew 14.2% YoY, ahead of industry production growth of 11.8%. Passenger vehicles grew 24% YoY, supported by utility vehicle demand, while commercial vehicles grew 34.1% and railways grew 40.1%.
- The railway business grew 40.1% in FY26 and is positioned to benefit from Vande Bharat, Vande Bharat Sleeper, LHB coach upgrades and electric locomotives. Gabriel has also developed dampers for Rajdhani, Shatabdi and Vande Bharat coaches. The commercial vehicle business, where Gabriel has around 88% market share, benefited from higher freight movement and infrastructure activity. Export opportunities with European and North American OEMs could provide an additional growth avenue.
- Gabriel has maintained around 60% market share with key EV customers in the two-wheeler segment and is supplying suspension products to Suzuki, Ultraviolette, River/Yamaha and TVS, with further programmes under development with Bajaj and other OEMs. The company is also gaining in premium motorcycles through inverted front forks, with new wins from Yamaha and Suzuki. In passenger vehicles, new programmes across EV and ICE models, including Tata Harrier, Safari and Nexon, should support content growth as the mix shifts towards SUVs and premium vehicles.
- Gabriel has over 40% market share in the aftermarket, supported by more than 800 dealers and 30,000 retail outlets. The business benefits from its established brand and distribution network and grew 16% in exports during FY26, with presence now extending across all six continents. The aftermarket also provides a more diversified revenue stream compared with OEM-dependent businesses and should remain an important support to overall growth.
- Inalfa Gabriel Sunroof Systems generated ₹434 crore revenue in FY26 with a 15% EBITDA margin. Gabriel is increasing its stake in the JV to 65%, subject to regulatory approvals. The second production line is being converted into a flexible manufacturing line for different sunroof architectures, which should improve utilisation as new models ramp up. Localisation has also increased from 26% to 32%, although competitive pricing remains a monitorable as new programmes are bid. Gabriel has approved the acquisition of 28.99% in HL Mando Anand India for ₹2,231 crore and around 30% in HL Klemove India for USD 98.4 million. HL Mando will add braking and steering to Gabriel's existing suspension portfolio, while HL Klemove provides exposure to ADAS and automotive electronics. The latter is particularly important as safety content per vehicle increases. The transactions also consolidate ANAND Group investments under the listed company and strengthen Gabriel's position as a broader automotive technology supplier.


Gabriel has a broader business portfolio and a stronger pipeline of OEM programmes across two-wheelers, passenger vehicles, commercial vehicles and railways. Two-wheelers should remain the core growth driver, supported by new customer wins, premiumisation and EV programmes, while the aftermarket, railways and commercial vehicles provide diversification. The sunroof business should benefit from higher utilisation and new model launches. The larger opportunity is the ongoing consolidation of ANAND Group businesses: Project Jupiter's investments in HL Mando Anand and HL Klemove India can materially expand Gabriel's presence in braking, steering and ADAS, increasing its technology content per vehicle and reducing dependence on suspension. Management expects Gabriel's share of ANAND Group sales to approach 70% following Project Jupiter. We recommend investing with a long-term perspective.

Standalone Financial Performance (Rs. Crore)

Year end	202603	202503	202403	202303	202203
Equity	14	14	14	14	14
Networth	1369	1183	1002	870	767
Total Debt	148	69	75	11	13
Net Sales	4667	4063	3403	2972	2332
Other Income	26	26	19	17	26
PBIDT	424	390	293	214	146
PAT	258	241	175	132	90
Book Value	95	82	70	61	53
EPS	18	17	12	9	6
Dividend (%)	500	470	400	255	155
Payout (%)	55	50	51	41	40

Latest Results (Rs. Crore)

Year	Jun-26	Jun-25	Mar-26	YoY (%)	QoQ (%)
Net Sales	1,426	1,234	1,381	15.50	3.25
Other Income	47	43	54	9.70	-12.78
PBIDT	172	161	186	6.28	-7.99
PBT	133	126	147	5.95	-9.61
PAT	107	105	119	1.99	-9.88



SUMITOMO CHEMICALS INDIA LIMITED

CMP (As on 31 August 2026) – 517.45

INDUSTRY - SPECIALTY CHEMICALS

SEPTEMBER 2026


Mkt. Cap.	: 25828.3 Cr
Equity	: 499 Cr
Trading Vol.	: 133240
52 Week High/Low	: 617.45/362.60
Face Value	: 10

BSE Group	: A
BSE Code	: 542920
NSE Symbol	: SUMICHEM
Bloomberg	: SUMICHEMIN
Reuters	: SUMH.BO

Shareholding Pattern	
Promoters	: 75.00
Institutions & Corporates	: 10.70
Foreign	: 3.56
Public & Others	: 10.74

The stock was earlier reviewed in our Sajag Online publication of September 2020. We continue to maintain a positive outlook of the company owing to stable financials, volume recovery and product launches as pricing and mix benefits have already supported margins.

Sumitomo Chemical India Ltd. (SCIL) is one of the leading players in the Indian crop protection industry, with a balanced portfolio of technical and formulation products and backward integration in select products. The company markets proprietary products of its Japanese parent, Sumitomo Chemical Company, across agrochemicals, animal nutrition and environmental health, while the integration of Excel Crop Care has strengthened its generic crop protection portfolio and distribution network. SCIL has 200+ brands and 700+ SKUs across insecticides, herbicides, fungicides, fumigants, plant growth regulators, biologicals and animal nutrition products. The company also has a growing export presence across Africa and other international markets.



Investment rationale

- Domestic revenue grew 4% in FY26, while branded formulations increased to 81% of domestic sales from 79%. Specialty products now account for around 30% of domestic revenue, while products launched over the last three years contribute around 8%. The focus on branded products, farmer engagement and demand generation should support better customer retention and product realisation over time.
- SCIL launched seven products during FY26, including Lentigo and Excalia Max, both of which received good market acceptance despite difficult weather conditions. Herbicides grew 19% during FY26 and 87% in Q4, supported by Flumioxazin, Lentigo and Mera 71. The company has visibility for further product launches over the next 3-5 years, with additional molecules awaiting regulatory approvals. This provides a pipeline for growth without relying only on existing products.
- Biologicals and biorationals already contribute around 8-10% of revenue, above the industry average of below 5%. Regulatory disruptions affected the segment during FY26, but approvals have started coming through.
- Exports declined marginally in FY26 due to shipment timing and softer demand, but the business continues to expand geographically. Export revenue declined 1% for the full year, while branded products now account for around 40% of export revenue. In Q1 FY27, exports recovered strongly, growing 26% YoY and contributing 16% of revenue, led by South America, Asia ex-India and Africa.
- SCIL has adopted a gradual product-wise price increase rather than a broad one-time increase. Price revisions were implemented during March, April and May, with further action considered as required. This approach, combined with a favourable product mix, helped FY26 gross margin improve by 107 bps to around 42% and EBITDA margin rise to 20.7%. Q1 FY27 showed the same trend, with gross margin improving 111 bps to 39.2% and EBITDA margin increasing 120 bps to 21.9%.
- SCIL remains essentially debt-free with around ₹2,113 crore of cash and liquid investments as of March 2026. Net worth increased 17% to ₹3,394 crore, while ROCE improved to 31% from 29%. Working capital increased to 103 days from 89 days due to higher inventory ahead of the kharif season, but receivable days improved from 91 to 83 days. The strong cash position provides flexibility to support product development, capacity expansion and other growth initiatives without balance-sheet stress.

The company expects growth from new products such as Top Grain and Helibax, while the recovery of biologicals and PGRs following regulatory approvals should support the portfolio. Overall, SCIL's key strength is its ability to maintain margins and cash generation despite weak industry conditions, supported by its branded portfolio, strong distribution network, proprietary products, new product pipeline and debt-free balance sheet. FY27 earnings growth will depend more on volume recovery and product launches as pricing and mix benefits have already supported margins. We recommend investing with a long-term perspective.

Consolidated Financial Performance (Rs. Crore)

Year	202603	202503	202403	202303	202203
Equity	499	499	499	499	499
Networth	3390	2901	2442	2382	1927
Total Debt	63	52	30	34	38
Net Sales	3238	3149	2844	3511	3061
Other Income	147	120	96	45	27
PBIDT	655	633	475	667	602
PAT	510	485	352	485	418
Book Value	68	58	49	48	39
EPS	11	10	7	10	8
Dividend (%)	13	12	59	12	10
Payout (%)	22	18	167	10	9

Latest Results (Rs. Crore)

Year	Jun-26	Jun-25	Mar-26	YoY(%)	QoQ(%)
Net Sales	1,063	1,057	684	0.62	55.52
Other Income	74	39	32	91.23	130.30
PBIDT	307	258	116	19.19	164.22
PBT	288	241	148	19.81	95.35
PAT	195	178	111	9.27	75.24

DR REDDYS LABORATORIES LIMITED

CMP (As on 31 August 2026) – 1154

INDUSTRY - PHARMACEUTICALS

SEPTEMBER 2026

Mkt. Cap.	: 96355.45 Cr
Equity	: 84 Cr
Trading Vol.	: 2001757
52 Week High/Low	: 1414/1101
Face Value	: 1

BSE Group	: A
BSE Code	: 500124
NSE Symbol	: DRREDDY
Bloomberg	: DRRDIN
Reuters	: REDY.BO

Shareholding Pattern	
Promoters	: 26.64
Institutions & Corporates	: 32.12
Foreign	: 21.77
Public & Others	: 8.47

The stock was earlier reviewed in our Sajag Online publication of January 2023. We continue to maintain a positive outlook of the company owing to differentiated offerings, expanding portfolio, sound financials and improving growth in Indian and other markets.

Dr. Reddy's Laboratories Ltd (DRL) is a diversified pharmaceutical company with operations across generics, biosimilars, APIs and pharmaceutical services. The company has a presence across the US, India, Europe, Emerging Markets and Russia/CIS, with Global Generics contributing 89% of FY26 revenue, PSAI 10% and other businesses 1%.

Investment rationale

- ▶ The US remained the largest geography at 33% of consolidated FY26 revenue, followed by India at 18%, Europe at 18% and Russia at 10%. DRL has been reducing its dependence on the US through growth in India and Emerging Markets, while increasing its focus on complex generics, peptides and biosimilars. In FY26, the company launched 199 products globally, filed 15 ANDAs in the US and continued to build its pipeline through products such as semaglutide and abatacept.
- ▶ India contributed 18% of FY26 revenue and grew 15.8% YoY to ₹6,220 Cr. Secondary sales grew 12.1% versus 9.9% for the Indian Pharmaceutical Market, with DRL ranked 9th in March 2026. The company has 443 branded products and more than 7,400 sales representatives in India. Growth was supported by the innovation portfolio, new launches, price increases, volume growth and the Stugeron portfolio. This business also carries better and more stable margins than the US generics business.
- ▶ The US contributed 33% of FY26 revenue, but revenue declined sharply after the loss of gRevlimid/lenalidomide contribution following patent expiry. Management continues to indicate double-digit growth in the underlying US base business excluding lenalidomide, supported by new launches and higher volumes. DRL filed 15 ANDAs in FY26, has 77 pending filings and is targeting 27 US launches in FY27, including complex products. The US remains an attractive opportunity but also exposes DRL to pricing pressure and USFDA-related risks.
- ▶ DRL launched bosutinib as a first-to-market product in the US with 180-day exclusivity for the 400 mg strength and also launched nintedanib. The company expects another US launch in FY27 with potential revenue of tens of millions of dollars. More importantly, semaglutide and biosimilars provide larger medium-term opportunities. The company was the first to receive Canadian approval for generic semaglutide injection and launched oral semaglutide in India, while the abatacept biosimilar remains targeted for US approval in December 2026.
- ▶ DRL is developing complex generics, peptides and biosimilars as part of its strategy to move towards higher-value products. The abatacept BLA remains targeted for December 2026 following a USFDA pre-license inspection at the Bachupally biologics facility, which resulted in seven Form 483 observations. Management considers these observations addressable and has submitted its response. If approved, management expects abatacept to be profitable from launch. The opportunity is strategically important as biologics currently account for only around 2% of sales, leaving significant room for growth. DRL continues to focus R&D on complex generics, biosimilars, peptides and novel biologics, with FY27 spending expected at 7-8% of revenue.
- ▶ DRL's Revenue translating into a 12.1% CAGR, while operating profit grew at a 10.8% CAGR. Net profit grew faster at 16.3% CAGR, supported by the strong improvement in FY23-25. EPS increased implying a 16.4% CAGR. DRL remained in a net cash position of around ₹1,830 Cr in FY26, with strong operating cash generation. The company incurred ₹2,300 Cr of capex in FY26 and plans around ₹2,000 Cr in FY27, mainly towards biosimilars, product-specific investments and general capex. Management has also indicated that the strong balance sheet can be used for inorganic opportunities across generics, innovation and biosimilars. This provides flexibility without putting significant pressure on leverage.

The company has traditionally been heavily dependent on generics, particularly the US market. However, its strategy is increasingly moving toward higher-value and more differentiated products-biosimilars, peptides, complex generics, consumer healthcare and innovative/digital healthcare offerings. This diversification is important because the underlying branded businesses-India, Emerging Markets and consumer health-already accounted for 52% of Q1 FY27 revenue, and management expects it to grow in double digits. Management expects gross margins to improve above 50% and remains focused on cost optimisation and productivity. Branded markets now contribute around 52% of revenue and provide a relatively stable margin base. At the same time, DRL continues to build its complex product pipeline through 27 planned US launches, biosimilars and peptides. We recommend investing with a long-term perspective.

Consolidated Financial Performance (Rs. Crore)

Year	202603	202503	202403	202303	202203
Equity	84	83	83	83	83
Networth	37892	33550	28255	23286	19212
Total Debt	7734	4677	2002	1347	3385
Net Sales	33700	32644	28011	24670	21545
Other Income	1372	1119	909	1093	555
PBIDT	6454	8547	7933	6349	3768
PAT	4007	5548	5512	4598	2111
Book Value	456	405	339	281	233
EPS	50	68	67	54	26
Dividend (%)	800	800	800	800	600
Payout (%)	32	23	24	11	19

Latest Results (Rs. Crore)

Year	Jun-26	Jun-25	Mar-26	YoY (%)	QoQ (%)
Net Sales	8,071	8,545	7,516	-5.56	7.37
Other Income	356	291	480	22.38	-25.94
PBIDT	1,215	2,464	862	-50.68	41.00
PBT	553	1,905	119	-70.96	362.24
PAT	444	1,418	220	-68.67	101.13

Source: Company, Capital line, Sajag Research



SAJAG STOCK HOTLINE 020 2530 24 00

CORPORATE ACTIONS IN SEPTEMBER 2026

Company Name	Record Date	Purpose
GAIL (India)	02-09-2026	5% Final Dividend
NTPC	02-09-2026	35% Final Dividend
Coal India	04-09-2026	Rs.5.25 per share (52.5%) Final Dividend
O N G C	04-09-2026	20% Final Dividend
Dixon Technologies	21-09-2026	Rs.10 per share (500%) Final Dividend

GAINERS AND LOSERS OF THE MONTH (NIFTY-50)

GAINERS			
COMPANY	OPEN	CLOSE	%
Eternal Ltd	303.5	310.5	8.11%
Grasim Industries Ltd	3120	3260	8.04%
Kotak Mahindra Bank Ltd	392	397.5	6.99%
Bharat Electronics Ltd	390	392.15	6.27%
Axis Bank Ltd	1236.9	1272	5.10%

LOSERS			
Company Name	Open	Close	%
SBI Life Insurance Company Ltd	1899	1740.5	-8.35%
Bharti Airtel Ltd	1987.4	1811.9	-8.83%
Bajaj Finance Ltd	1176.3	1057	-10.14%
ITC Ltd	284.45	255.5	-10.18%
Tata Motors Passenger Vehicles Ltd	344.5	308.85	-10.35%

INVESTMENT IDEAS - MEDIUM TERM (3-6 MONTHS)

BHARTI AIRTEL LTD. (BAL)

CMP (AS ON 31 AUGUST 2026) - 1814 TARGET - 2159

BAL is a leading global telecommunications service provider with over 650 million customers across 17 countries in Asia and Africa. In India, the company provides mobile, 5G, broadband, DTH, fixed-line and enterprise services, while its Africa operations span 14 countries. BAL is the second-largest telecom operator in India, with wireless subscriber market share of 37.9% and broadband subscriber market share of 35.4% as of May 2026. FY26 consolidated revenue grew 22% YoY to ₹2.11 lakh crore, while EBITDA increased 28% to ₹1.20 lakh crore, with EBITDA margin improving to 56.7% from 53.9%. India mobility accounted for 53.6% of FY26 consolidated revenue, followed by Airtel Africa at 26.9%, Indus Towers at 15.4% and enterprise solutions at 10.0%, providing diversification across geographies and business segments. During FY26, BAL increased its stake in Indus Towers to 51.26%, resulting in its consolidation as a subsidiary from November 2025. Q1 FY27 maintained the growth momentum, with consolidated revenue rising 5.7% QoQ to ₹58,500 crore and EBITDA increasing 4.2% QoQ to ₹29,800 crore, while net debt/EBITDA improved further to 0.7x. India mobile added 3.3 million revenue-earning customers and 5 million smartphone data customers during the quarter, with ARPU increasing to ₹264. Growth opportunities are also emerging from Airtel Money, Nxtra's data-centre expansion, Airtel Business, cloud and lending, while continued cost optimisation under the 'War on Waste' programme and strong cash generation should support further deleveraging. Management remains focused on improving monetisation through customer upgrades, higher data consumption and postpaid penetration, although it highlighted the need for a more sustainable industry pricing architecture.

JTEKT India Limited (JIL)

CMP (AS ON 31 AUGUST 2026) - 124 TARGET - 179

JTEKT India Limited (JIL) is a leading manufacturer of steering systems and driveline products for passenger vehicle OEMs in India, with a market leadership position in steering systems and strong share of business with major OEMs including Maruti Suzuki, Mahindra & Mahindra, Honda, Toyota and Tata Motors. Around 95% of its revenue is derived from the domestic passenger vehicle segment, while its product portfolio spans manual and power steering systems, steering gears and columns, case differentials, axle assemblies, propeller shafts and constant velocity joints (CVJs). The Company benefits from strong parentage through JTEKT Corporation, Japan, which provides technical support and access to Japanese OEMs. JIL reported revenue growth of 11.1% YoY to ₹2,665.6 crore in FY26, ahead of domestic PV industry growth of around 9%, supported by higher volumes from Maruti Suzuki and new model launches. However, EBITDA margin remained broadly stable at 7.5% compared with 7.6% in FY25, as volume-led operating leverage in 2H was offset by an adverse customer mix, with higher contribution from relatively lower-margin Maruti volumes and lower volumes from Honda, Toyota and export programmes. Q1 FY27 demand remained supportive, with continued ramp-up of new platforms and growth in the driveline business. CVJ is emerging as an important growth driver, with additional capacity already operational and utilisation expected to increase as new programmes ramp up, including the upcoming Maruti EV programme. The Company has also commenced exports to Brazil for Stellantis, with volumes expected to increase meaningfully over the next few years, providing an opportunity to improve its export mix, which remains below FY24 levels. JIL is simultaneously expanding its manufacturing footprint, including the new Gujarat plant, while FY27 capex is expected to moderate as the major investment cycle progresses. Management expects margins to improve as volumes increase, new programmes ramp up, product mix normalises and cost-efficiency initiatives take effect.

We have the authorised persons at following locations

Area	Contact Person	Tel. No.	Area	Contact Person	Tel. No.
Aundh	Mr. Jaydeep Doshi	25890824	Koregaon Park	Mr. Ajit Godbole/Mr. Ninad Parundekar	26158889
Boat Club Road	Mr. Naresh Karpe	41204584	Paud Road	Mr. Sadanand Damle	9850845567
Camp	Mr. Naresh Karpe	26346310	Phadke Haud	Mr. Jayant Mundada	9850990766
Dahanukar Colony	Mr. Abhay Oak	25444744	Sahakar Nagar	Mr. Tejas Jaykar	9765173434
ITI Road, Aundh	Mr. Ravi Jadhav	25888511	Aurangabad	Mr. Amit Vaidya	0240-2347584
Kalyani Nagar	Ms. Bernadette Dias	9422449266	Aurangabad	Mr. Abhijit Bhairwal	0240-2361421
Karve Nagar	Ms. Prajakta Bedekar	8600993930	Satara	Mr. Vinod Jhamvar	02162-233906
Kondhwa	Mr. Santosh Gupte	26836366	Shrirampur	Mr. Amit Somani	02422-228111

***For opening your account with us and Net Trading
please contact Kiran - 020 6601 47 37***

FOR PRIVATE CIRCULATION TO THE REGISTERED CLIENTS OF SAJAG SECURITIES PVT LTD ONLY

CERTIFICATION:

This report is issued by Sajag Securities Pvt. Ltd. (SSPL) which is regulated by SEBI and its research activities are as per SEBI Guidelines for Research Analysts December 2014. Registration Number: INH000001923
The research analyst(s) who prepared this research report hereby certifies that the views expressed in this research report accurately reflect the research analyst's personal views about all of the subject issuers and / or securities, that the analyst have no known conflict of interest and no part of the research analyst's compensation was, is or will be, directly or indirectly, related to the specific views or recommendations contained in this research report. It is confirmed that the Research Analyst do not serve as an officer, director or employee of the companies mentioned in the report.

Disclaimer (As per SEBI (Research Analyst) Regulations, 2014)

Investments in securities markets are subject to market risks and there is no assurance or guarantee that the objectives of the investments/investment products/clients will be achieved. Past performance is not indicative of future returns. Investors are advised to review the Client Agreement and other related documents carefully and, in its entirety, and consult their legal, tax and financial advisers to determine possible legal, tax and financial or any other consequences of investing.

This Report has been prepared by Sajag Securities Private Limited, a SEBI-registered Research Analyst (Registration No. INH000001923) and is for informational purposes only. The views and opinions expressed herein are those of the author as of the date of publication and are subject to change without notice. This Report does not constitute investment advice or an offer or solicitation for the purchase or sale of any financial instrument or security.

The information contained in this Report has been obtained from publicly available sources believed to be reliable, but no representation or warranty, express or implied, is made regarding its accuracy or completeness. Investors should make their own investment decisions based on their specific objectives, financial situation, and needs, and should consult their financial adviser before making any investment decision.

Sajag Securities Private Limited accepts no liability whatsoever for any direct or consequential loss or damage arising from any use of any information in this document. While utmost diligence has been exercised regarding the accuracy of information contained in this document, please independently verify such information before relying on it.

Analyst Certification: Sajag Securities Pvt Ltd, hereby certifies that all views expressed in this research report reflect personal views about the subject company(ies) or securities, and no part of any compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) expressed herein.

Disclosure of Interest: Unless otherwise specified in Point No. 9 below:

- Neither the Research Analyst(s), Sajag Securities Pvt. Ltd., nor its associates or the relatives of the Research Analyst have any financial interest in the company(ies) covered in this report.
- The Research Analyst, his/her associates, relatives, and Sajag Securities Pvt. Ltd. have no other material conflict of interest at the time of publication of this research report.
- Neither the Research Analyst, Sajag Securities Pvt. Ltd., nor its associates have received any compensation for investment banking,

merchant banking, brokerage services, or any other products/services from the company(ies) covered in this report in the past twelve months.

- Neither the Research Analyst, Sajag Securities Pvt. Ltd., nor its associates have managed or co-managed any private or public offering of securities for the company(ies) covered in this report in the past twelve months.
- Sajag Securities Pvt. Ltd. or its associates have not received any compensation or other benefits from the company(ies) covered in this report, or from any third party, in connection with this research report.
- The Research Analyst has not served as an Officer, Director, or employee of the company(ies) covered in this research report.
- The Research Analyst and Sajag Securities Pvt. Ltd. have not been engaged in any market-making activity for the company(ies) covered in this research report.

9. Details pertaining to Sajag Securities Pvt. Ltd., Research Analyst, and its associates with respect to the companies covered in this research report:

Sr. No.	Particulars	Yes/No
1	Compensation received from the company(ies) covered in this research report for investment banking transactions in the past 12 months by Sajag Securities Pvt. Ltd.	No
2	Research Analyst, Sajag Securities Pvt. Ltd., or its associates/relatives collectively hold more than 1% of the company(ies) covered in this research report	No
3	Compensation received by Sajag Securities Pvt. Ltd. or its associates from the company(ies) covered in this research report	No
4	Sajag Securities Pvt. Ltd. or its affiliates managed or co-managed, in the previous twelve months, a private or public offering of securities for the company(ies) covered in this research report	No
5	Research Analyst, his/her associates, Sajag Securities Pvt. Ltd., or its associates received compensation for investment banking, merchant banking, brokerage services, or any other products/services from the company(ies) covered in this research report in the past twelve months	No

Contact : RASHMI, Tel.No. : 020 6601 47 37 or send e-mail at 'rashmi@sajag.co.in' for further clarification.